Hypnosis may quiet the night: a Drug-Free approach to sleepwalking

NCT ID NCT05953207

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This trial compares medical hypnosis with standard sleep hygiene education for people who experience NREM parasomnias—such as sleepwalking, confusional arousals, or sleep terrors. Participants attend three treatment sessions and have their sleep monitored with home video recordings and sleep diaries. The goal is to see whether hypnosis can reduce the number and severity of these episodes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
medical hypnosis
What this could lead to
If effective, medical hypnosis could offer a drug-free way to reduce sleepwalking and related episodes.
What could go wrong
This is a small, early-stage trial, and hypnosis may not work for everyone. Results may not apply to all parasomnia patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

110 people

The number who actually took part.

Started

Aug 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients with NREM parasomnia (N=60): Inclusion Criteria: * Non-REM parasomnias diagnosis according to the international classification disease of sleep disorders * Willling and able to give informed consent * Reporting at least one parasomniac episode per month * Reporting at least one parasomniac episode the month prior Exclusion Criteria: * Refusal to use the home video recording device * Current or planned intake (during the next 2 months) of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines) * A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia) * A comorbid sleep disorder (e.g., apnea-hypopnea index (AHI) \>= 20/hour, REM sleep behaviour disorder, restless legs syndrome with symptoms more than 2 days/week) * A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder) Healthy volunteers (N=50): Inclusion Criteria: \- Adult (≥ 18 yo) willing and able to give informed consent. Exclusion criteria: * Presence of NREM parasomnias diagnosis, or any other concomitant sleep disorder; * Current intake of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines); * A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia); * A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder); * Current history of psychiatric or neurological disorders (e.g., migraines).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nrem parasomnia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre hospitalier universitaire vaudois (CHUV)

    Lausanne, Canton of Vaud, 1005, Switzerland